Take-Home Naloxone for Opioid Analgesic Patients
The most appropriate reason to prescribe take-home naloxone to a patient taking opioid analgesics is when they are receiving ≥50 morphine milligram equivalents (MME) per day, or when they are taking opioids concurrently with benzodiazepines, gabapentinoids, or other sedating agents. 1
Primary Indications for Naloxone Co-Prescription
The 2023 ASCO guideline provides the clearest framework for naloxone prescribing in patients on chronic opioid therapy 1:
High-Priority Patients:
- Dose threshold: Patients receiving ≥50 MME daily
- Polypharmacy risk: Concurrent use of benzodiazepines, gabapentinoids, or other sedating medications
- Household safety: Concern for unintended access by children or cognitively impaired family members
Additional Risk Factors to Consider:
- History of previous opioid overdose 2, 3
- Concomitant substance use disorder 3
- Ongoing alcohol use 2
- High-dose opioid therapy (some sources suggest >90 MME as upper limit) 4
Clinical Reasoning
The rationale for these specific thresholds is straightforward: respiratory depression is the mechanism by which opioid overdose causes death 5. While tolerance to sedation typically develops within days of opioid initiation, the combination of opioids with other CNS depressants dramatically increases overdose risk 1.
Important Nuance:
The guideline evidence suggests naloxone should be considered even for patients on lower doses if other risk factors are present. A 2016 study found that when providers were advised to offer naloxone to all patients on long-term opioids, they appropriately prioritized those with established risk factors, including patients on higher doses and those with prior opioid-related emergency department visits 6.
Practical Implementation
Do not wait for signs of overdose to prescribe naloxone - this is a preventive measure. The prescription should include:
- Patient and caregiver education on recognizing overdose signs (severe sedation, respiratory depression)
- Administration technique for intranasal or intramuscular routes 5
- Emphasis on calling emergency services - naloxone's half-life is shorter than many opioids, and respiratory depression can recur 5, 7
Common Pitfall:
Documentation of naloxone education is frequently inadequate - one study found 69% of naloxone dispenses lacked documentation that patients received proper education 3. Ensure both the prescription AND the education are documented.
Special Populations
For cancer pain patients, the same principles apply, though the guideline specifically notes that naloxone administration should be "consistent with patient's goals of care at the end of life" 1. This acknowledges that some terminally ill patients may prioritize comfort over overdose prevention.
For elderly patients (≥65 years), providers report high likelihood (83.9%) of prescribing naloxone, recognizing increased vulnerability due to polypharmacy and comorbidities 8, 2.
What Naloxone Does NOT Indicate
Prescribing naloxone does not mean you expect the patient to overdose - it's harm reduction. Studies show that 99.1% of providers who prescribed naloxone were likely to prescribe it again, and most (73.9%) felt it did not affect their opioid prescribing practices 8. Only 3.6% felt they might prescribe more opioids after providing naloxone, dispelling concerns about "moral hazard."
Evidence Quality Note
The strongest evidence comes from the 2023 ASCO guideline 1, which provides the most recent and specific recommendations for naloxone co-prescribing thresholds. The 2020 and 2015 AHA guidelines 7, 5 focus primarily on acute overdose management rather than preventive co-prescribing, though they establish naloxone's excellent safety profile and effectiveness.